A Two Period, 2 Sequence Crossover To Establish The Relative Bioavailability Of A Single Pf-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2011
At a glance
- Drugs PF 4634817 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Adverse reactions; Pharmacokinetics
- 31 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jan 2011 Planned End Date changed from 1 Nov 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 06 Dec 2010 New trial record